Spectrum Pharmaceuticals, Inc. Release: Multifaceted Repositioning Campaign for ZEVALIN® Unveiled at American Society of Hematology 2011, Following Recent FDA Approval to Remove Bioscan Requirement

HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology and hematology, announced today the launch of the Company’s re-positioning campaign for ZEVALIN® (ibritumomab tiuxetan) at the 2011 Annual Meeting of the American Society of Hematology being held December 10-13.